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PURE RED CELL APLASIA AFTER ABO
MAJOR-MISMATCHED ALLOGENEIC PERIPHERAL BLOOD
STEM CELL TRANSPLANTATION SUCCESSFULLY TREATED
WITH PLASMA EXCHANGE AND LOW-DOSE STEROID:
TWO CASE REPORTS
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Pure red cell aplasia (PRCA) is a complication of ABO-incompatible allogeneic stem cell transplantation.
The mechanism is not well known, although the isoagglutinin titer before transplantation or cyclosporine
use is considered to be the cause. Patients with this complication require more blood transfusions than
those without it. There is no standard treatment. We report two cases of PRCA after allogeneic peripheral
blood stem cell transplantation that were successfully treated with plasma exchange and low-dose steroid.
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Allogeneic bone marrow transplantation (BMT) and peri-
pheral blood stem cell transplantation (PBSCT) from hu-
man leukocyte antigen (HLA)-identical related or unre-
lated donors are used to treat various hematologic di-
seases. There is ABO incompatibility between donor and
recipient in about 20% of HLA-identical BMTs or PBSCTs
[1]. Blood group incompatibility does not appear to deter-
mine the outcome of BMT or PBSCT, including engraftment
of white blood cells (WBCs) and platelets, incidence of graft
rejection and graft-versus-host disease (GVHD), and sur-
vival [2–4]. Pure red cell aplasia (PRCA) is observed in a
minority of ABO major-mismatched BMT or PBSCT re-
cipients [1,4,5]. Various treatment strategies have been
used, including cyclosporine discontinuation [4,5], ster-
oid [6], erythropoietin [7,8], antithymocyte globulin [9], do-
nor leukocyte infusion (DLI) [10], anti CD-20 monoclonal
antibody [11], plasma exchange [1,4,12], and a combinat-
ion of any of these. Spontaneous recovery has also been re-
ported [4,13]. However, there is no definitive standard man-
agement. We report two cases of PRCA that developed after
ABO major-mismatched PBSCT from HLA-identical re-
lated donors. Both cases were successfully treated with
plasma exchange and low-dose steroid.
CASE PRESENTATIONS
Case 1
This 20-year-old male with severe aplastic anemia presented
in December 2000 with a WBC count of 2,860/+L, a hemo-
globin of 5.6 g/dL, and a platelet count of 16,000/+L. He
received HLA-identical, ABO major-mismatched (donor:
AB, recipient: O) PBSCT from his younger sister in March
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2001, with a conditioning regimen of total body irradiation
(TBI; 300 cGy) and cyclophosphamide (50 mg/m2) for 4
days. Prophylaxis for GVHD was provided by intravenous
cyclosporine and a short course of methotrexate.
Engraftment of WBCs and platelets was observed on
day 14. Stage I GVHD in skin was noted but no treatment
was required. Anemia with low reticulocyte counts persist-
ed after transplantation without evidence of hemolysis.
Complete donor chimerism was noted on day 26. Bone
marrow study on days 14 and 26 showed the absence of
erythroid cells. The patient received a blood transfusion of
2 units about every 2 weeks. Isoagglutinin titers were high
before transplantation (anti-A/anti-B: 128/128), had
transiently declined by day 15 (anti-A/anti-B: 16/8), and
were elevated again on day 27 (anti-A/anti-B: 128/64).
Plasma exchange with 18 units (one plasma volume) AB
type was performed four times every 2 days from day 27,
but anemia and reticulocytopenia persisted even though a
low anti-A/anti-B titer (16/2) was achieved by day 170.
Blood transfusions were still needed during this period.
Plasma exchange was repeated five times every 2 days from
day 170, but anemia persisted without transfusion. Cy-
closporine was given orally from day 22 (150 mg bid re-
duced to 125 mg bid, 100 mg bid, and 100 mg qd from days
68, 190, and 309, respectively). It was withheld completely
after day 344. Prednisolone (30 mg/day) was prescribed
from day 225 (45 days after the last course of plasma ex-
change).
Reticulocytosis (reticulocyte count > 1%) and elevation
of the hemoglobin level were observed on day 268 (43 days
after initiation of steroids), with no further blood transfu-
sions required thereafter. Prednisolone was withheld for 8
days during the 43-day period because of fever. Prednisolone
was reduced gradually from day 281 with no further drops
in hemoglobin level. On day 317, bone marrow showed a
normal picture with adequate erythropoiesis. The blood
type had also transformed to AB (Figure 1).
Case 2
A 36-year-old male patient suffering from leukocytosis, Ph
chromosome positivity, and splenomegaly was diagnosed
with chronic myelogenous leukemia (CML) in the chronic
phase in April 1999. He received one locus HLA-mismatch,
ABO major-mismatched allogeneic PBSCT (donor: A, reci-
pient: O) from his brother in May 2000, with a conditioning
regimen of fractionated TBI (200 cGy twice a day for 3 days)
and cyclophosphamide (60 mg/m2 for 2 days). GVHD
prophylaxis was provided by intravenous cyclosporine and
a short course of methotrexate.
The absolute neutrophil count was more than 500/+L on
day 9 and the platelet count was more than 20,000/+L on
day 16. The chromosomal abnormality was converted to a
normal karyotype (46,XY) using bone marrow aspiration on
day 10. Chimerism had shifted to the donor type on day 33.
He had persistent anemia and was dependent on blood
transfusion, but there was no GVHD. On days 10 and 33,
there was a deficit of red blood cell (RBC) precursor cells in
the bone marrow compatible with PRCA. Coombs’ test,
cytomegalovirus polymerase chain reaction (PCR) test, and
Parvo B19 PCR test were all negative.
Cyclosporine was given orally from day 26 (150 mg bid
reduced to 100 mg bid, 75 mg bid, 50 mg bid, and 75 mg qd
from days 61, 82, 103, and 227, respectively). It was withheld
completely after day 315. During cyclosporine tapering,
there was no evidence of reticulocytosis. Low-dose pred-
nisolone (15 mg/day) was prescribed from day 234. The
anti-A titer was 8 at that time. Anemia and reticulocytopenia
persisted for 71 days after initiation of steroid therapy. Be-
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Figure 1. Case 1: he-
moglobin, reticulocyte
count, and anti-A titer
over time.
  reticulocyte
  anti-A titer
◆   Hb
120
105
90
75
60
45
30
15
0
A
nt
i-A
 t
ite
r
re
tic
ul
oc
yt
e 
= 
10
-3
Days after PBSCT
Plasma exchange
IV Oral 150 mg bid 125 mg bid
Prednisolone
Plasma exchange
14
12
10
8
6
4
2
0
H
b g/dL
100 mg bidCyclosporine
-1 28 40 68 99 127 155 177 204 231 261 288 316
Kaohsiung J Med Sci March 2004 • Vol 20 • No 3
H.J. Tsai, S.F. Lin, T.C. Liu, et al
130
◆
◆◆◆◆◆
◆◆◆
◆
◆◆◆◆
◆
◆◆
◆
◆◆ ◆◆◆ ◆ ◆ ◆◆◆
◆◆◆ ◆ ◆ ◆◆ ◆
◆
◆ ◆
◆ ◆ ◆ ◆
cause there was no response to low-dose steroid, plasma
exchange with 18 units (one plasma volume) of AB type
was added four times every 2 days from day 305. Reticu-
locytosis was noted 18 days after the last plasma exchange.
No further blood transfusions were needed after discon-
tinuation of prednisolone. On day 809, bone marrow showed
a normal picture with adequate red cell series and full
chimerism (Figure 2).
DISCUSSION
ABO major-mismatched transplant carries a risk of he-
molysis at the time of stem cell transfusion or post trans-
plantation [14], and delayed erythroid engraftment has
also been reported. In general, isoagglutinins against
RBC precursors are considered responsible for the occur-
rence of PRCA in patients receiving ABO-incompatible
BMT or PBSCT [4,10,12,14]. The mechanism of PRCA after
major ABO-incompatible hematopoietic stem cell trans-
plantation is unclear, but the presence of recipient isoag-
glutinins against ABH antigen on donor red cells may play
an important role.
Reticulocytopenia may persist for a long time even
when there is a low isoagglutinin titer, with or without
management, including vigorous plasma exchange or
intravenous immunoglobulin [1,3,7,15]. In our two cases,
low isoagglutinin titers after plasma exchange or steroid
alone did not achieve effective erythropoiesis. Low iso-
agglutinin titer alone cannot explain the whole mecha-
nism of erythropoiesis after ABO major-mismatched trans-
plantation. How low an isoagglutinin titer is needed to
achieve effective erythropoiesis? Is a mechanism other than
isoagglutinin associated with red cell aplasia?
Cyclosporine was thought to be one cause of PRCA.
However, although there is an increased incidence of PRCA
in patients receiving cyclosporine as GVHD prophylaxis
[4], erythropoiesis occurs after discontinuation of cyclo-
sporine [5]. PRCA does not resolve after discontinuation
of cyclosporine in all cases [10]. In Case 1, reticulocytosis
occurred on day 268, when cyclosporine had been decreased
to a steady dose of 100 mg bid for 78 days. Erythropoiesis
seemed not to be correlated with cyclosporine tapering
because cyclosporine was maintained at the same dosage.
In Case 2, cyclosporine was tapered to 50 mg bid, half of the
initial dose, from day 103. This continued for 104 days when
the dose was decreased to 75 mg qd (on day 227) for 88 days.
Cyclosporine was discontinued completely on day 315.
Although it seemed that reticulocytosis occurred 14 days
after discontinuation of cyclosporine, the 212 days of low-
dose cyclosporine seemed too long a period to be the cause
of erythropoiesis in this case.
Anti-A isoagglutinin is considered a risk factor for the
increased incidence of PRCA [3]. Case 1 had anti-A and anti-
B isoagglutinin against donor RBCs and Case 2 had anti-A
isoagglutinin against donor RBCs. Some cases with anti-B
isoagglutinin alone develop PRCA [1,6,12].
Many treatment options for PRCA after ABO major-
mismatched transplantation have been reported. Pulsed
and high-dose steroids have been successfully used to treat
such cases. To prevent side effects caused by high doses,
especially the potential opportunistic infections due to
immunosuppression, we decided to use low-dose steroid.
This was prescribed initially for Case 2, but no response was
observed after 71 days. Plasma exchange was performed
concomitantly with steroid administration. In Case 1, plasma
exchange was performed initially and a low isoagglutinin
titer was achieved, but effective erythropoiesis occurred
Figure 2. Case 2: he-
moglobin, reticulocyte
count, and anti-A titer
over time.
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only after low-dose steroid was initiated. Although many
cases of PRCA have been successfully treated using plasma
exchange alone, it seemed ineffective in our cases, in which
combined low-dose steroid and plasma exchange were
effective for PRCA after ABO major-mismatched allogeneic
PBSCT. We suggest that plasma exchange plays a role in
clearing isoagglutinin rapidly and steroid inhibits the
production of isoagglutinin by plasma cells derived from
residual memory B lymphocytes. However, when plasma
exchange should be initiated and how frequently it should
be performed, and the adequate dose of steroid to be used
remain questions for further investigation. Indeed, delayed
erythropoiesis occurred in spite of low isoagglutinin titers
in our two cases. It seemed that there must be factors other
than isoagglutinins contributing to the development of
PRCA, and these need to be investigated.
In conclusion, from our limited two-case experience,
PRCA after ABO major-mismatched transplantation can
be successfully treated with low-dose steroid and plasma
exchange.
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